ZEVRA THERAPEUTICS, INC. (ZVRA) Form 8-K — Aug 5, 2026
Zevra Therapeutics reported Q2 2026 net revenue of $39.7 million, a 53% increase over Q2 2025, driven by $30.2 million of MIPLYFFA net revenue in Niemann-Pick disease type C. MIPLYFFA added 14 new prescription enrollment forms in the quarter, bringing the total to 184 since launch, with market access stable at 69% of covered lives. The company posted GAAP net income of $8.8 million, or $0.14 per basic and diluted share, and adjusted net income of $15.2 million, or $0.25 per diluted share, a swing from an adjusted loss of $2.4 million a year ago. Operating expenses fell to $21.0 million from $24.2 million, with SG&A down $4.2 million.
Key figures
- Eps
- 0.14
- Revenue
- 39663000
- Net Income
- 8752000
- Total Debt
- 0
- Revenue Yoy
- 53% increase over Q2 2025 ($25.9 million)
- Total Assets
- 302712000
- Cash Position
- 260200000
- Shares Outstanding
- 59341906
- Orange book listing
- through 2041
- Rnd expense q2 2026
- $4.5 million
- Sga expense q2 2026
- $16.6 million
- Fully diluted shares
- 69298105
- Six month revenue 2026
- 75883000
- Warrant shares issuable
- 2529379
- Six month net income 2026
- 46642000
- Long term debt dec 31 2025
- $61.9 million (eliminated by June 30, 2026)
- Adjusted net income q2 2026
- $15.2 million (non-GAAP)
- Market access covered lives
- 69%
- Olpruva net revenue q2 2026
- $0.2 million
- Adjusted diluted eps q2 2026
- 0.25
- Global eap patients enrolled
- 132
- Miplyffa net revenue q2 2026
- $30.2 million
- Eap net reimbursements q2 2026
- $9.0 million
- Discover trial confirmed events
- 3
- Discover trial patients enrolled
- 66
- Total operating expenses q2 2026
- $21.0 million (vs $24.2 million Q2 2025)
- Azstarys royalties and other q2 2026
- $0.3 million
- New miplyffa enrollment forms q2 2026
- 14
- Miplyffa total enrollment forms since launch
- 184
Price after filing
Close on the filing date to close N calendar days later (from $10.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.